Lieping Chen
陈列平
MD, PhD
United Technologies Corporation Professor in Cancer Research; Professor of Immunobiology, Medicine, and Dermatology联合技术公司癌症研究教授；免疫生物学、内科学与皮肤科教授
👥Biography 个人简介
Discoverer of B7-H1 (PD-L1) and pioneer of the PD-1/PD-L1 immune checkpoint axis. His foundational research established that tumor-expressed PD-L1 suppresses anti-tumor immunity and that blocking this interaction restores T cell killing, laying the conceptual and scientific groundwork for modern checkpoint immunotherapy.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Discovery of PD-L1 (B7-H1)
Cloned and characterized B7-H1 (now PD-L1) as a novel B7 family member expressed on tumor cells, demonstrating its inhibitory function on T cell responses and its role in enabling tumor immune escape.
PD-L1 as a Tumor Immune Evasion Mechanism
Provided the first evidence that tumor-expressed PD-L1 suppresses anti-tumor T cell responses in vivo and that antibody blockade of this interaction restores tumor rejection, establishing the therapeutic hypothesis for checkpoint inhibitors.
Normalization Cancer Immunotherapy Concept
Developed the concept of 'cancer immunotherapy normalization' — restoring normal immune checkpoint balance rather than global immune activation — providing a framework for precision combination immunotherapy with reduced toxicity.
Representative Works 代表性著作
B7-H1, a Third Member of the B7 Family, Co-stimulates T-Cell Proliferation and Interleukin-10 Secretion
Nature Medicine (1999)
Original cloning and characterization of B7-H1/PD-L1, establishing its immune regulatory function and its expression on tumor cells.
Involvement of PD-L1 on Tumor Cells in the Escape from Host Immune System
Proceedings of the National Academy of Sciences (2002)
Demonstrated that tumor cell-expressed PD-L1 suppresses anti-tumor T cell immunity in vivo, providing the mechanistic foundation for PD-L1-targeted cancer therapy.
Normalization of Tumour Vasculature: An Emerging Concept in Antiangiogenic Therapy
Nature Reviews Cancer (2022)
Proposed normalization as a unifying principle for precision checkpoint immunotherapy, advocating combination strategies that restore immune homeostasis in the tumor microenvironment.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 陈列平 的研究动态
Follow Lieping Chen's research updates
留下邮箱，当我们发布与 Lieping Chen（Yale University School of Medicine / Yale Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment